NCT04345419View on ClinicalTrials.gov

Remdesivir Efficacy in Coronavirus Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
COVID
Interventions
DRUG

Remdesivir

Remdesivir as antiviral drug

OTHER

Standard of care treatment

Standard of care treatment

Trial Locations (1)

Unknown

Tanta university hospital, Assuit University, Ainshams University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT04345419 - Remdesivir Efficacy in Coronavirus Disease | Biotech Hunter | Biotech Hunter